AGRX: AI 评分 59/100 — AI 分析 (4月 2026)

Agile Therapeutics, Inc. is a pioneering women's healthcare company focused on developing innovative prescription contraceptive products. With its lead product, Twirla, and a robust pipeline, Agile aims to address unmet needs in women's health.

Key Facts: Price: $1.51 AI Score: 59/100 Sector: Healthcare

公司概况

概要：

Agile Therapeutics, Inc. is revolutionizing women's healthcare with its innovative contraceptive solutions, including the once-weekly Twirla patch, targeting a growing market of women seeking effective and convenient birth control options.

AGRX是做什么的？

Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics, Inc. is a trailblazer in women's healthcare, focusing on the research, development, and commercialization of prescription contraceptive products. The company has developed its flagship product, Twirla (AG200-15), a once-weekly combination hormonal contraceptive patch that offers women an alternative to daily oral contraceptives. Twirla is designed to provide effective birth control with the convenience of weekly application, addressing the needs of women seeking reliable contraceptive options. Agile Therapeutics is also actively expanding its product line with several promising pipeline extensions. These include the AG200-15 Extended Regimen (ER), which allows for fewer withdrawal bleeding episodes, and the AG200-15 smaller patch (SmP), designed to enhance contraceptive efficacy while providing shorter and lighter withdrawal bleeds. Additionally, the company is developing the P-Patch, a progestin-only contraceptive patch for women who cannot or choose not to take estrogen. Agile's commitment to innovation in women's health is evident in its strategic focus on creating products that cater to diverse needs, thereby positioning itself as a key player in the women's contraceptive market.

AGRX的投资论点是什么？

Investing in Agile Therapeutics, Inc. presents a compelling opportunity due to its focus on the underserved women's healthcare market, particularly in contraceptive solutions. With a market cap of $0.01 billion and a gross margin of 54.2%, Agile demonstrates potential for profitability as it expands its product offerings. The launch of Twirla has already established a foothold in the market, and the development of line extensions could drive revenue growth significantly. The contraceptive market is projected to grow steadily, and Agile's innovative products are well-positioned to capture market share. With a pipeline that includes multiple products targeting various needs, Agile is poised for growth as it addresses the evolving preferences of women regarding contraceptive options. The company's unique value proposition lies in its commitment to developing convenient and effective solutions, which could lead to increased adoption and a stronger market presence over the next five years.

AGRX在哪个行业运营？

The drug manufacturing industry, particularly in specialty and generic segments, is experiencing robust growth driven by increasing demand for innovative healthcare solutions. The global contraceptive market is projected to reach $30 billion by 2027, with a growing emphasis on convenience and efficacy in contraceptive methods. Agile Therapeutics operates within this expanding market, competing with companies like BFFTF, CNPOF, EMHTF, EXDI, and FLWPF. Agile's focus on developing unique contraceptive solutions positions it favorably against traditional methods and emerging competitors, as it addresses the evolving needs of women seeking effective birth control options.

Healthcare/Drug Manufacturers - Specialty & Generic

Healthcare

AGRX有哪些增长机遇？

Growth opportunity 1: The U.S. contraceptive market is projected to grow at a CAGR of 4.5% through 2027, driven by increasing awareness and demand for effective birth control methods. Agile's innovative products, such as Twirla and its line extensions, are well-positioned to capture a significant share of this growing market, especially among women seeking alternatives to traditional contraceptives.
Growth opportunity 2: Agile's pipeline includes the AG200-15 Extended Regimen (ER), which allows for fewer withdrawal bleeding episodes. This product targets a specific consumer need, potentially attracting women looking for more flexible contraceptive options. The anticipated launch in 2025 could significantly boost revenue, tapping into a market segment that values convenience.
Growth opportunity 3: The development of the AG200-15 smaller patch (SmP) aims to enhance contraceptive efficacy while providing shorter and lighter withdrawal bleeds. This product is expected to appeal to younger women and those new to hormonal contraceptives, expanding Agile's customer base and market reach as it targets an estimated 10 million women in the U.S. alone.
Growth opportunity 4: The P-Patch, a progestin-only contraceptive patch, addresses the needs of women unable or unwilling to take estrogen. This product could open new market segments, particularly among women with specific health concerns or preferences, potentially increasing Agile's market penetration and sales.
Growth opportunity 5: Agile's strategic partnerships with healthcare providers and pharmacies could enhance distribution channels, increasing product accessibility. By leveraging these relationships, Agile can improve market presence and drive sales growth, particularly as it expands its product offerings.

Market cap of $0.01 billion indicates significant growth potential in the women's healthcare sector.
Gross margin of 54.2% reflects Agile's ability to maintain profitability as it scales operations.
P/E ratio of -0.23 suggests current financial challenges, but potential for turnaround with successful product launches.
Beta of 1.58 indicates higher volatility compared to the market, presenting both risks and opportunities for investors.
No dividend yield currently, indicating a focus on reinvestment into product development and growth.

AGRX提供哪些产品和服务？

Research and develop prescription contraceptive products for women.
Commercialize innovative contraceptive solutions like Twirla.
Create line extensions to enhance existing products.
Focus on women's health and address unmet needs in contraceptive options.
Develop progestin-only contraceptive solutions for diverse consumer needs.
Engage in strategic partnerships to improve product distribution.

AGRX如何赚钱？

Generate revenue through the sale of prescription contraceptive products.
Focus on innovative product development to capture market share.
Leverage partnerships with healthcare providers for better distribution.
Invest in marketing and education to promote product awareness.
Aim for profitability through cost management and efficient operations.

Women seeking effective and convenient contraceptive options.
Healthcare providers prescribing contraceptive solutions.
Pharmacies and healthcare facilities distributing Agile's products.
Women with specific health needs, such as those unable to take estrogen.
Young women looking for flexible contraceptive methods.

Innovative product offerings that address specific consumer needs.
Strong focus on women's health, differentiating Agile from competitors.
Established brand presence with Twirla in the contraceptive market.
Pipeline of future products enhancing long-term growth potential.
Strategic partnerships improving market access and distribution.

什么因素可能推动AGRX股价上涨？

Upcoming: Launch of AG200-15 Extended Regimen (ER) expected in 2025.
Ongoing: Continued sales growth of Twirla as awareness increases.
Upcoming: Development and potential launch of the P-Patch targeting specific consumer needs.
Ongoing: Expansion of marketing efforts to promote new product offerings.
Upcoming: Strategic partnerships aimed at improving distribution channels.

AGRX的主要风险是什么？

Potential: Regulatory hurdles could delay product launches.
Ongoing: Competition from larger pharmaceutical companies impacting market share.
Potential: Changes in healthcare policies affecting contraceptive access.
Ongoing: Financial instability due to negative profit margins.

AGRX的核心优势是什么？

Innovative product pipeline addressing unmet needs in women's health.
Established market presence with Twirla as a leading contraceptive option.
Strong gross margin of 54.2%, indicating efficient operations.
Focused expertise in women's healthcare, enhancing credibility.

AGRX的劣势是什么？

Current negative profit margin of -73.8%, indicating financial challenges.
Limited product portfolio compared to larger competitors.
Small workforce of 19 employees, potentially limiting operational capacity.
Dependence on a single product (Twirla) for revenue generation.

AGRX有哪些机遇？

Growing demand for innovative contraceptive solutions in the U.S. market.
Expansion of product offerings through line extensions and new products.
Potential for strategic partnerships to enhance distribution and market reach.
Increasing awareness and acceptance of women's health issues.

AGRX面临哪些威胁？

Intense competition from established pharmaceutical companies.
Regulatory challenges in the drug approval process.
Market volatility affecting stock performance and investor confidence.
Changing consumer preferences in contraceptive methods.

AGRX的竞争对手是谁？

Bayer AG — A major player in the contraceptive market with a broad product range. — (BFFTF)
Cypress Pharmaceuticals — Focuses on niche pharmaceutical products, including contraceptives. — (CNPOF)
Eton Pharmaceuticals — Develops specialty pharmaceuticals, including women's health products. — (EMHTF)
Exelixis, Inc. — Engages in the development of innovative therapies, including in women's health. — (EXDI)
Ferring Pharmaceuticals — Specializes in reproductive health and fertility solutions. — (FLWPF)

Key Metrics

Price: $1.51 (+3.42%)
Market Cap: $10.4M
Volume: 119,291
MoonshotScore: 59/100

Company Profile

CEO: Alfred F. Altomari
Headquarters: Princeton, NJ, US
Employees: 19
Founded: 2014

AI Insight

常见问题

What does Agile Therapeutics, Inc. do?

Agile Therapeutics, Inc. is a women's healthcare company that specializes in the research, development, and commercialization of prescription contraceptive products. Its lead product, Twirla, is a once-weekly hormonal contraceptive patch designed to provide women with an effective and convenient birth control option. The company is also developing additional products, including line extensions and alternative contraceptive solutions, to address diverse consumer needs in the contraceptive market.

Is AGRX stock a good buy?

AGRX stock presents a mixed investment opportunity. While the current market cap of $0.01 billion and gross margin of 54.2% indicate potential for growth, the negative P/E ratio of -0.23 and profit margin of -73.8% raise concerns about financial stability. the may be worth researching upcoming product launches and the overall growth potential of the contraceptive market before making investment decisions.

What are the main risks for AGRX?

Agile Therapeutics faces several risks that could impact its performance. These include potential regulatory hurdles that may delay product launches, ongoing competition from larger pharmaceutical companies that could affect market share, and financial instability stemming from a negative profit margin. Additionally, changes in healthcare policies could influence contraceptive access, further complicating the company's growth trajectory.